Skip to main content

Table 6 Summary statistics for the clinician efficacy scores in the first 24 hours after surgery

From: Robenacoxib versus meloxicam for the control of peri-operative pain and inflammation associated with orthopaedic surgery in cats: a randomised clinical trial

Response Visits Robenacoxib (s.c. + oral) Meloxicam s.c. + oral placebo P value (Mann–Whitney test) Quotient robenacoxib:meloxicam (RMANCOVA) P value (RMANCOVA) Transformation for RMANCOVA analysis
   Mean (SD) Mean (SD)   Mean 95% CI   Transformation P value for normality (Shapiro-Wilks test)
Global investigator score (primary end point) V2-V4 2.72 (1.42) 2.80 (1.62) 0.76 1.029 0.847–1.231 0.76 0 (log) 0.20
Posture V2-V4 0.68 (0.53) 0.79 (0.61) 0.38 1.144 0.821–1.538 0.39 −1 (reciprocal) <0.0001
Behaviour V2-V4 0.81 (0.56) 0.88 (0.64) 0.91 1.073 0.827–1.360 0.58 −0.5 (reciprocal of square root) 0.024
Pain on palpation/manipulation V2-V4 1.22 (0.69) 1.14 (0.69) 0.23 0.979 0.799–1.184 0.82 0.5 (square root) 0.0024
Overall pain control V2-V4 1.17 (0.76) 1.15 (0.67) 0.89 1.120 0.880–1.408 0.34 0.5 (square root) 0.011
Sedation V2-V4 0.44 (0.44) 0.40 (0.42) 0.76 0.945 0.396–1.755 0.85 −0.5 (reciprocal of square root) 0.024
  1. CI: confidence interval; s.c.: subcutaneous.
  2. Values are mean (SD) for each group and quotient values with 95% CIs for the ratio robenacoxib/meloxicam. Data are from the assessments at V2, V3 and V4. Non-inferiority of robenacoxib versus meloxicam was concluded if the lower limit of the 95% CI was >0.75 (shown in bold). P values <0.05 are also shown in bold.
  3. The global investigator score (the primary end point) ranged from 0 to 9. All other end points (secondary end points) ranged from 0 to 3.